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ABSTRACT  24 
 While natural hepatitis C virus (HCV) infection results in highly diverse quasispecies of 25 
related viruses over time, mutations accumulate more slowly in tissue culture, in part because of 26 
the inefficiency of replication in cells. To create a highly diverse population of HCV particles in 27 
cell culture and identify novel growth-enhancing mutations, we engineered a library of infectious 28 
HCV with all codons represented at most positions in the ectodomain of the E2 gene. We 29 
identified many putative growth adaptive mutations and selected nine highly represented E2 30 
mutants for further study: Q412R, T416R, S449P, T563V, A579R, L619T, V626S, K632T, and 31 
L644I. We evaluated these mutants for changes in particle to infectious unit ratio, sensitivity to 32 
neutralizing antibody or CD81 large extracellular loop (CD81-LEL) inhibition, entry factor usage, 33 
and buoyant density profiles. Q412R, T416R, S449P, T563V and L619T were neutralized more 34 
efficiently by anti-E2 antibodies and T416R, T563V and L619T by CD81-LEL. Remarkably, all 35 
nine variants showed reduced dependence on scavenger receptor class B type I (SR-BI) for 36 
infection. This shift from SR-BI usage did not correlate with a change in the buoyant density 37 
profiles of the variants, suggesting an altered E2-SR-BI interaction rather than changes in the 38 
virus-associated lipoprotein-E2 interaction. Our results demonstrate that residues influencing 39 
SR-BI usage are distributed across E2 and support the development of large scale mutagenesis 40 
studies to identify viral variants with unique functional properties.  41 
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IMPORTANCE  43 
 Characterizing variant viruses can reveal new information about the lifecycle of 44 
Hepatitis C virus (HCV) and the roles played by different viral genes. However, it is difficult to 45 
recapitulate high levels of diversity in the laboratory because of limitations in the HCV culture 46 
system. To overcome this limitation, we engineered a library of mutations into the E2 gene in 47 
the context of an infectious clone of the virus. We used this library of viruses to identify nine 48 
mutations that enhance the growth rate of HCV. These growth enhancing mutations reduced the 49 
dependence on a key entry receptor, scavenger receptor class B type I (SR-BI). By generating a 50 
highly diverse library of infectious HCV, we mapped regions of the E2 protein that influence a 51 
key virus-host interaction and provide proof-of-principle for the generation of large-scale mutant 52 
libraries for the study of pathogens with great sequence variability.  53 
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 Hepatitis C virus (HCV) infection causes a major global health burden, as 56 
approximately 3% of the world's population is affected (1). Up to 30% of individuals with HCV 57 
will resolve infection spontaneously, whereas the majority develop chronic infections that can 58 
cause fibrosis, cirrhosis, and hepatocellular carcinoma (2). HCV is a member of the hepacivirus 59 
genus of the Flaviviridae family of RNA viruses, and is a positive-sense, enveloped virus with a 60 
9.6 kilobase genome. The genome comprises a single open reading frame encoding an 61 
approximately 3,000 amino acid polyprotein flanked by 5′- and 3′- noncoding regions. HCV 62 
primarily infects and replicates in hepatocytes, and its lifecycle is tied intimately to the 63 
lipoprotein biosynthesis pathway. HCV particles incorporate host lipoproteins forming a 64 
"lipoviroparticle" with unique properties when compared to other Flaviviridae members (3, 4).     65 
 HCV is divided into 7 genotypes and 67 subtypes and exists as a quasispecies within 66 
a host (5).  Natural HCV isolates exhibit considerable diversity in their genomic sequences, 67 
however it is difficult to recapitulate the extent of this variability in vitro. Recent advances have 68 
made it possible to infect cells in culture with human-derived HCV isolates and observe genome 69 
replication, but new infectious particles still cannot be generated readily from clinical samples 70 
(6). The study of cell culture infectious HCV relies on a few, relatively slow-growing infectious 71 
clones (7–13). These clones do not acquire growth adaptive mutations rapidly during passaging 72 
despite the high error rate of the HCV polymerase, possibly because of the limited production of 73 
new infectious virions.  74 
 HCV has two envelope glycoproteins, E1 and E2. The E2 gene is a protein of 75 
particular variability and is under selection pressure from adaptive immune responses during an 76 
extended chronic infection (14, 15). In conjunction with virus-associated lipoprotein, the 77 
envelope proteins mediate attachment and entry of the virus into host cells (16). E1 and E2 form 78 
non-covalently linked trimers of disulfide-linked heterodimers on the virion surface (17, 18). Two 79 
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structural biology (19, 20). E2 core has a compact, globular structure consisting mainly of 81 
random coils and β-strands. While several structural features of E2 have well-described 82 
functions in the HCV lifecycle, the contributions of other regions of the protein are less well 83 
understood (21–24).  84 
 To study an HCV population containing an array of single amino acid variants, we 85 
created a genotype 2a JFH-1 isolate library with maximal diversity in the E2 gene. We 86 
generated a site-directed saturation mutagenesis (SDSM) library from a JFH-1-derived 87 
infectious clone, which allowed us to explore almost the entire sequence space for single-codon 88 
substitutions in E2. We used the library to identify novel E2 growth adaptive mutations. After 89 
only three passages, nine mutations in different regions of the protein were identified and 90 
confirmed to have growth kinetic advantages: Q412R, T416R, S449P, T563V, A579R, L619T, 91 
V626S, K632T, and L644I. These mutants had varying profiles with respect to neutralizing 92 
monoclonal antibody (NMAb) and CD81 large extracellular loop (CD81-LEL) sensitivity. 93 
However, all of these mutations yielded a reduced dependence on scavenger receptor class B 94 
type I (SR-BI) for entry even though they were distributed across several regions of E2. Our 95 
study provides insight into the molecular determinants of the interaction between SR-BI and E2 96 
and acts as proof-of-principle for the use of large scale variant libraries to address questions in 97 
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METHODS AND MATERIALS 99 
Cell culture. Huh7.5 cells were obtained as a gift (C. Rice, Rockefeller University) and 100 
maintained in Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher Scientific) 101 
supplemented with 10% fetal bovine serum (FBS, Equitech-Bio), MEM nonessential amino 102 
acids, and penicillin/streptomycin (Corning).    103 
Plasmid library and virus production. The plasmid pLJ83, which encodes the JFH-1 104 
HCV infectious clone bearing adaptive mutations outside of the E2 gene, was a generous gift 105 
(G. Luo, University of Alabama, Birmingham) (25) and used for our SDSM library. Unless noted 106 
in the text, all amino acid residues numbers refer to the JFH-1 genome (26). Three hundred and 107 
twenty complementary primer sets containing random nucleotides at all three positions of a 108 
single codon within the E2 gene were designed and ordered from Integrated DNA Technologies. 109 
All residues between amino acid positions 384 and 721 in the polyprotein were targeted, 110 
excluding cysteines (positions 429, 452, 459, 488, 496, 505, 510, 554, 566, 571, 585, 589, 601, 111 
611, 624, 648, 656, and 681). Each primer set was used to amplify variants by polymerase 112 
chain reaction (PCR) from pLJ83 using a Phusion® high fidelity polymerase kit (New England 113 
Biolabs). The PCR products were digested with DpnI (New England Biolabs) and transformed in 114 
library-grade MegaX® DH10B T1R electrocompetent cells (Thermo Fisher Scientific).  115 
 Plasmids were prepared from bacterial cultures using plasmid Maxi-prep kits (Qiagen) 116 
from sets of ten sequential codon libraries generated by SDSM. The 32 pooled plasmid libraries 117 
corresponded to the following amino acids: 384-393, 394-403, 404-413, 414-423, 424-434, 435-118 
444, 445-455, 456-466, 467-476, 477-486, 487-498, 499-509, 511-520, 521-530, 531-540, 541-119 
550, 551-561, 562-573, 574-583, 584-595, 596-606, 607-617, 618-628, 629-638, 639-649, 650-120 
660, 661-670, 671-680, 682-691, 692-701, 702-711 and 712-721. The plasmids were linearized 121 
by digestion with NruI (New England BioLabs), purified, and genomic RNA was synthesized 122 
using a MEGAscript T7 transcription kit (Ambion). Infectious HCV was generated after 123 
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4 x 106 Huh7.5 cells, and virus was harvested 48, 72, 96, and 120 h later. HEPES pH 7.3 (10 125 
mM) was added to the virus-containing supernatants for storage at 4oC prior to concentration 126 
with Amicon Ultra 100,000 kDa MWCO centrifugal filters (EMD Millipore). Concentrated virus 127 
stocks were stored at -80oC and titered using the 50% tissue culture infectious dose (TCID50) 128 
method (27).  129 
Amplicon sequencing of plasmid libraries. The 32 sets of pooled plasmids described 130 
above were analyzed using next generation sequencing to determine the diversity of the library. 131 
An approximately 2 kilobase fragment corresponding to the E1 and E2 genes was amplified by 132 
PCR from each of the 32 plasmid pools and submitted for Ampicon-seq library preparation and 133 
Illumina HiSeq sequencing (single end 50 basepair reads) at the Genome Technology Access 134 
Center at Washington University. Reads were aligned to the pLJ83 sequence using Bowtie2. 135 
Reads containing insertion or deletions were not considered, and the remaining reads were 136 
counted to determine codon frequency using a custom script.  137 
Focus-forming assay. Infectious HCV was detected using a focus-forming assay (FFA) 138 
on Huh7.5 cells. Briefly, 6.4 x 103 Huh7.5 cells were plated in individual wells of a 96-well plate 139 
treated with of poly-L-lysine one day prior to infection. Three days later, cells were rinsed with 140 
PBS, fixed and permeabilized with cold methanol, rinsed again and incubated in blocking 141 
solution (PBS containing 1% BSA and 0.2% skim milk). Subsequently, the cells were incubated 142 
with 100 ng/mL anti-NS5A mAb (9E10, a gift of C. Rice, Rockefeller University (9)), rinsed 143 
again, and incubated with 1:2000 dilution of horseradish peroxidase conjugated goat anti-mouse 144 
IgG (Sigma). Virally-infected cell foci were visualized using TrueBlue™ peroxidase reagent 145 
(KPL) and quantified using an S5 Biospot™ Macroanalyzer (Cellular Technologies Ltd).  146 
Selection of mutations in E2 that confer increased HCV growth. Parallel cultures of 147 
3.8 x 104 Huh7.5 cells were infected with 1 x 104 TCID50 of each of 32 HCV mutant pools 148 
containing engineered diversity at ten sequential positions in E2. Input viruses were removed 6 149 





ber 21, 2016 by W







new Huh7.5 cells. This process was performed twice for a total of three passages. After the third 151 
passage, viral RNA was harvested using QIAamp® viral RNA mini kits (Qiagen) from all 32 final 152 
passage viruses, cDNAs were synthesized using the Superscript III® first strand synthesis 153 
system (Invitrogen), and DNA fragments corresponding to the E1-E2 fragment were amplified 154 
by PCR. Each PCR product was sequenced across the region of the E2 gene containing the 155 
sites of engineered mutations in the original pool. If changes to the consensus sequence were 156 
observed, the exact combinations of nucleotide substitutions at any given codon were 157 
determined using a Zero Blunt® TOPO® PCR Cloning Kit (Invitrogen) to generate individual 158 
bacterial colonies bearing unique E1-E2 sequences. Nine mutations identified from the TOPO 159 
cloning results were introduced into pLJ83 using conventional site-directed mutagenesis. 160 
Following verification of the complete genome sequence of the mutant plasmids, all nine clonal 161 
mutant viruses were generated as described above. Three of the nine selected mutations 162 
(S449P, L619T and L644I) also were introduced into a JFH-1-derived chimeric infectious clone 163 
encoding the structural genes of the genotype 1 H77 isolate (H77/JFH-1) at homologous 164 
positions in the E2 gene (28). The corresponding mutations in the H77 strain were S449P, 165 
L615T and L640I. Virus was produced exactly as described above, except an XbaI instead of 166 
NruI restriction enzyme digestion was performed prior to in vitro RNA production.  167 
Alignment of genotype 2 E2 amino acid sequences. To determine if the substitutions 168 
selected were present in circulating HCV strains, an alignment of genotype 2 E2 sequences was 169 
generated using the NIAID Virus Pathogen Database and Analysis Resource (ViPR) 170 
(http://www.viprbrc.org/) (29). 171 
HCV growth analysis. Huh7.5 cells were infected at a multiplicity of infection (MOI) of 172 
0.1 with parent virus or clonal growth-adapted mutants. Input viruses were removed 6 h post-173 
infection and samples collected every 24 h for seven days. Viral yield in the supernatant was 174 
quantified by FFA. The FFA protocol increased the apparent number of infectious units of 175 
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cells by the mutants. We therefore performed a second growth kinetic analysis using the TCID50 177 
method of virus titration to quantify virus. Huh7.5 cells were infected at an MOI of 0.05 with each 178 
of the clonal growth-adapted mutants as described above, and viral yield in supernatant was 179 
collected 5 days post-infection and calculated.  180 
HCV genome quantification. qRT-PCR was used to quantify genome copy number in 181 
virus-containing supernatants. Viral RNA was harvested using QIAamp® Viral RNA Mini Kit 182 
(Qiagen). All reactions were prepared using a TaqMan® RNA-to-CT™ (Applied Biosystems), 183 
with forward primer 5′-GATAAACCCACTCTATGCCCG-3′, reverse primer 5′-184 
CTATCAGGCAGTACCACAAGG-3′, and probe 5′-5′-/56-FAM/CTTTCGCAACCCAACGCTACT 185 
CG-/36-TAMSp/-3′. Run conditions were 48oC for 15 min, 95oC for 10 min, and then 40 cycles of 186 
95oC for 15 s an 60oC for 1 min. In vitro transcribed genomic transcripts were used as 187 
standards.  188 
Inhibition of HCV infection by anti-E2 NMAbs and CD81 large extracellular loop. 189 
Two-hundred TCID50 of parent or mutant viruses were pre-incubated with a dilution series of 190 
anti-E2 antibody or CD81-LEL for 1 h at 37oC and then added to Huh7.5 cells. Infection was 191 
quantified 72 h later by FFA, and EC50 values determined after performing non-linear regression 192 
analysis. Anti-E2 antibodies HC84.26 (a gift of S. Foung, Stanford University) and H77.39 have 193 
been described (30, 31). To generate soluble CD81-LEL, residues 114-203 of human CD81 194 
were cloned into a Pet28(+)-derived vector with a thrombin cleavable C-terminal BirA 195 
biotinylation site and 6xHis tag. CD81-LEL was produced by isopropyl β-D-1-196 
thiogalactopyranoside induction in BL21-DE3 E. coli cells and purified by oxidative refolding 197 
from inclusion bodies (32). Briefly, bacterial cell pellets were resuspended in a 1:1 mixture of 198 
solution buffer (50 mM Tris [pH 8.0], 25% sucrose, 10 mM dithiothreitol [DTT]), and lysis buffer 199 
(50 mM Tris [pH 8.0], 1% Triton X-100, 100 mM NaCl, 10 mM DTT). The sample was lysed by 200 
sonication and centrifuged, and the pellets were washed three times with wash buffer (50 mM 201 
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Triton X-100 to obtain purified inclusion bodies. The purified inclusion body pellets were 203 
resuspended in TE buffer (10 mM Tris [pH 8.0], 1 mM EDTA), and aliquots of the slurry were 204 
solubilized in 6 M guanidine-HCl, 10 mM Tris (pH 8.0), and 20 mM β-mercaptoethanol. 205 
Solubilized aliquots were diluted rapidly into a stirring reservoir of oxidative refolding buffer (400 206 
mM L-Arginine, 100 mM Tris [pH 8.0], 0.5 mM oxidized glutathione, 5 mM reduced glutathione) 207 
followed by overnight incubation. The refolded CD81-LEL then was purified by size-exclusion 208 
chromatography.  209 
Inhibition of infection by antibodies against HCV entry factors. Huh7.5 cells were 210 
treated with serially diluted anti-CD81, anti-claudin-1 (CLDN1), or anti-SR-BI antibodies for 1 h 211 
at 37oC and then infected with 200 TCID50 of parent or mutant viruses. Infection was quantified 212 
72 h later by FFA, and EC50 values were determined after non-linear regression analysis. Anti-213 
CD81 (clone JS-81) was purchased from BD Biosciences, and anti-CLDN1 (clone 5.16v5, a gift 214 
of I. Hotzel, Genentech), and anti-SR-BI (clone mAb16-71, a gift of A. Nicosia, CEINGE 215 
Biotecnologie Avanzate, Naples, Italy) were obtained from colleagues (33, 34).  216 
 CRISPR/Cas9 mediated gene editing of SR-BI. To perform CRISPR/Cas9 mediated 217 
gene editing, we generated expression plasmids encoding the U6 promoter in front of SR-BI 218 
specific guide RNAs (35). Two rounds of overlapping PCR were performed by amplifying a 219 
guide RNA encoding plasmid (provided by George Church, Harvard University, Boston, MA, 220 
Addgene plasmid # 41819): in the first round, PCR products were generated encompassing the 221 
U6 promoter through the 5′ end of the guide RNA (consisting of the specific target sequence) 222 
with the ME-O-1122 oligonucleotide (5′-CGGGCCCCCCCTCGAGTGTACAAAAAAGCAGGCT-223 
3′) and an SR-BI target sequence specific reverse oligonucleotide (see list below). A second 224 
PCR product was generated encompassing a region from the SR-BI target sequence through 225 
the end of the guide RNA coding sequence with a forward direction CLDN1 target sequence 226 
specific oligonucleotide (ME-O-1138; 5′-GCTTCATTCTCGCCTTCCGTTTTAGAGCTAGAAATA-227 
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1123, to produce single PCR products flanked by XhoI and EcoRI sites at the 5′ and 3′ ends, 229 
respectively, that were cloned into pBlueScript. Four separate SR-BI specific gRNA plasmids 230 
were created with the following forward and reverse oligonucleotide combination: ME-O-231 
1241/1242; 5′-CTGCTCCGCCAAAGCGCGC GTTTTAGAGCTAGAAATA-3’ / 5’-232 
GCGCGCTTTGGCGGAGCAG CGGTGTTTCGTCCTTTCC-3′, ME-O-1243/1244; 5′-233 
GGCCCTACGTGTACAGGTG GTTTTAGAGCTAGAA ATA-3′ / 5′-234 
CACCTGTACACGTAGGGCC CGGTGTTTCGTCCTTTCC-3′, ME-O-1245/1246; 5′-235 
CCCTCCAAGTCCCACGGCT GTTTTAGAGCTAGAAATA-3′ / 5′-236 
AGCCGTGGGACTTGGAGGG CGGTGTTTCGTCCTTTCC-3′, and ME-O-1247/1248; 5′-237 
GATCCACCTCGTGGACAAG GTTTTAGAGCTAGAAATA-3′ / 5′- CTTGTCCACGAGGTGGATC 238 
CGGTGTTTCGTCCTTTCC-3′, which target nucleotides 5259-5277, 51409-51427, 53942-239 
53960, and 57068-57086 of the SR-BI human genomic locus (relative to Genbank accession 240 
number NG_028199), respectively.  241 
 Huh7.5 cells were transiently transfected with expression plasmids encoding a human 242 
codon optimized Cas9 protein from Streptococcus pyogenes (provided by George Church, 243 
Harvard University, Boston, MA, Addgene plasmid # 41815) (35) and a pooled mixture of the 244 
above SR-BI guide RNA expression plasmids. Transfected cells were passaged for one to two 245 
weeks to allow the turnover of previously translated target protein. Cells were then subjected to 246 
fluorescence activated cell sorting (FACS) for loss of SR-BI following staining with the anti-SR-247 
B1 antibody (mAb16-71) and a goat anti-human Alexa-647 antibody (Invitrogen, Carlsbad, CA). 248 
Knockout of SR-BI efficiency prior to sorting was 11-15%. Single cell clones were obtained by 249 
limiting dilution cloning in 96-well plates. Individual clones were expanded and assayed for SR-250 
BI expression by flow cytometry with the mAb16-71 antibody, and the capacity to support HCV 251 
infection, as previously described (9). We chose Huh7.5 SR-BIKO clone 16 as a representative 252 
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 Lentiviral transduction of SR-BIKO Huh7.5. Transgene expression through lentiviral 254 
transduction was used to complement SR-BIKO cells. To express GFP alone, the self-255 
inactivating lentiviral provirus TRIP-GFP-linker was used (31). For SR-BI expression, the TRIP-256 
GFP-hu-SR-BI-linker provirus was used. VSV-G pseudotyped lentiviral stocks were produced in 257 
293T cells, as previously described (31, 36). Supernatants were collected 2 days post 258 
transfection and used to infect gene-edited Huh7.5 cells, also as previously described (31, 36). 259 
Cells were expanded for at least two weeks prior to analysis. 260 
Infection of SR-BI gene-edited Huh7.5 cells. SRBIKO+GFP or SRBIKO+GFP+SR-BI 261 
cells (1 x 105) were plated in wells of a poly-L-lysine treated 96-well plate one day prior to 262 
infection. Seventy-five TCID50 of virus per well were added, and three days later the plates were 263 
developed by FFA. Relative infection was calculated by determining the percent of foci present 264 
in SRBIKO+GFP wells compared to SRBIKO+GFP+SRBI wells for each virus.  265 
Virus attachment to gene-edited Huh7.5 cells. SR-BIKO+GFP or SRBIKO+GFP+SR-BI 266 
cells (5 x 105) in suspension were incubated with 5 x 104 TCID50 of virus for 3 h on ice. Cells 267 
were washed 6 times with chilled media and cellular RNA was harvested using a Qiagen 268 
RNeasy® Mini Kit. Viral genome copies were measured by qRT-PCR as described above. 269 
Relative attachment was calculated by determining the percentage of viral RNA bound to 270 
SRBIKO+GFP cells compared to SRBIKO+GFP+SRBI cells for each WT and mutant virus.  271 
Sucrose density gradient ultracentrifugation. HCV was ultracentrifuged using 5-50% 272 
(w/v) sucrose gradient ultracentrifugation. Sucrose solutions were prepared in TEN buffer (0.01 273 
M Tris, pH 8.0; 1 mM EDTA, and 100 mM NaCl) using a Gradient Master (Biocomp). The 274 
viruses were ultracentrifuged for 17 h at 4oC and 105,000 x g (Beckman SW41 Ti) and 1 ml 275 
fractions were collected and titered by FFA. The number of genome copies in each fraction was 276 
determined by RT-PCR as described above. Fraction densities were measured using an ABBE-277 
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Statistical analysis. Statistical analyses were performed using GraphPad Prism 279 
software. Differences in mean EC50 values, relative infections, titers or RNA:TCID50 values 280 
between the mutants and parent virus were analyzed by one way-ANOVA followed by a 281 
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 Isolation of adaptive JFH-1 variants by passage of a library containing 284 
mutagenized E2 genes. Several growth adaptive mutations have been previously identified in 285 
E2 and studying the properties of these mutants is an established method of linking structural 286 
features of E2 with functions in the virus lifecycle (37–41). Past attempts to identify growth 287 
adaptive mutations in the HCV genome have relied on serial passage of a clonal virus stock for 288 
weeks or months until adaptive mutations arise (25, 38–50). To identify adaptive mutations 289 
more expediently, we created a library of infectious HCV with a fully mutagenized E2 290 
ectodomain (Fig 1A). Three hundred and twenty primer sets containing three random 291 
nucleotides (NNN) corresponding to one codon in the ectodomain of E2 were designed. Using 292 
these primers and a JFH-1 infectious clone plasmid, we performed separate SDSM reactions 293 
with each primer pair yielding 320 plasmid libraries. To simplify production of infectious virus, we 294 
grouped the plasmid libraries into 32 sets of 10 adjacent codons for all downstream steps. To 295 
confirm that each plasmid library contained 64 engineered variants (all nucleotide combinations 296 
at each codon) we performed amplicon sequencing of the 32 sets of 10 pooled single codon 297 
plasmid libraries (Fig 1B). Under ideal conditions we expected a 10% mutation rate for a single 298 
codon within the ten plasmid pool containing variability at that position; our library had an 299 
average mutation rate of 6.0%. To produce infectious HCV, we transcribed RNA genomes in 300 
vitro from the pooled plasmids and electroporated each of 32 RNA stocks into Huh7.5 cells. By 301 
the end of this process, we had created 32 viral "pools" with each containing maximum 302 
variability at ten positions in E2.     303 
 Following virus production, cultures of Huh7.5 cells were inoculated with 104 TCID50 of 304 
each of the 32 mutant pools at a MOI of 0.3. Input virus was removed 6 h after infection and 305 
newly produced virus was collected 7 days later. This output virus was used to infect Huh7.5 306 
cells serially twice more after which Sanger sequencing of HCV E2 RT-PCR products was 307 
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of E2 within the region containing engineered variability. To determine the specific substitutions 309 
that were enriched by passaging, we generated cDNA from P3 viruses, and TOPO-cloned the 310 
E1-E2 genome fragment amplicons produced by PCR. We sequenced the E2 gene for 24 to 48 311 
resultant bacterial colonies from each of the 8 P3 viruses with consensus sequence changes 312 
(Table 1).  313 
 Based on these results, nine variants that corresponded to the dominant amino acid 314 
substitution in each of the P3 viruses were selected for further study: Q412R, T416R, S449P, 315 
T563V, A579R, L619T, V626S, K632T, and L644I. Four of these residues (Q412, T416, S449 316 
and T563) are at or very near to positions in E2 that have been reported as adaptive mutations 317 
(38–41, 45), with the remainder not having been described to affect growth. Sequencing of 318 
individual clones suggested that multiple substitutions at a given position might confer growth 319 
advantage over the parent virus with the exception of S449, which had only proline 320 
substitutions. S449P also was unique, as it eliminated a predicted N-linked glycosylation site at 321 
N448.  322 
 Clonal mutant viruses show enhanced growth kinetics. We used conventional site 323 
directed mutagenesis to introduce the nine dominant mutations into the parental infectious 324 
clone. Following verification by complete genome sequencing of the plasmids, mutant viruses 325 
were generated after electroporation of in vitro derived RNA into Huh7.5 cells and titered using 326 
the TCID50 method. To validate the significance of the mutations, multi-step viral growth 327 
analyses were performed by FFA after infection of Huh7.5 cells (MOI of 0.1) with each mutant 328 
and the parental virus (Fig 2A). Whereas each of the mutations conferred a growth advantage 329 
compared to the parental virus, we noticed that the input virus titer (t = 0) for all of the mutant 330 
viruses appeared higher than the parent JFH-1 in this assay. Because we inoculated with 331 
equivalent input amounts based on the TCID50 assay, we hypothesized that the difference at t = 332 
0 of the input virus reflected the more rapid growth of the adaptive mutant strains over the 333 
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a second confirmatory viral growth assay. Cultures of Huh7.5 cells were infected at an MOI of 335 
0.05 (as determined by TCID50 assay) with the mutant and parent viruses, and supernatants 336 
were collected five days later and titered by TCID50 assay (Fig 2B). Using this second method, 337 
the mutants exhibited a 5- and 10-fold growth advantage compared to the parental viruses. In 338 
this assay, the V626S mutant did not show a statistically significant growth advantage compared 339 
to the parental strains. Nonetheless, it may still be a growth adaptive mutation based on 340 
accumulated data (Table 1, Fig 2). 341 
  Particle to infectious unit ratios for E2 mutants. We next explored whether there 342 
were functional differences in the properties of growth-adapted viruses compared to the parent 343 
JFH-1 strain. We initially assessed the relative specific infectivity by measuring the RNA:TCID50 344 
ratio of each mutant virus (Table 2). A more efficient assembly process or increased stability of 345 
infectious virions could contribute to increased peak titers. As HCV growth kinetic assays are 346 
long, small differences may compound over time and account for at least part of the adaptive 347 
growth phenotype. Using the tittered samples described in Fig 2B, viral RNA was harvested and 348 
genome copy determined via RT-PCR using in vitro derived-RNA from infectious clone plasmids 349 
as standards. The greatest difference between parent and a mutant virus was observed for 350 
T563V, and even this fold-change was less than 4-fold. All mutant viruses, apart from K632T, 351 
had a lower RNA:TCID50 ratio than the parental virus, although these differences did not 352 
achieve statistical significance.   353 
Buoyant density profiles of growth adapted mutants are similar to parent. HCV has 354 
a unique buoyant density profile when compared to many other Flaviviridae family members 355 
(e.g., flaviviruses). Because of lipoprotein incorporation, infectious HCV particles have a lower 356 
density and broader infectivity peak (3, 4). Some E2 growth variants have altered buoyant 357 
density profiles relative to their parental strains (37, 40), and such differences may reflect 358 
alterations in lipoprotein incorporation or changes to the subset of HCV particles (high or low 359 
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had shifts in buoyant density profiles, we performed sucrose gradient ultracentrifugation and 361 
quantified the density, viral titer, and HCV genome copy number in each fraction collected (Fig 362 
3). The mutants all behaved similarly to parent virus, suggesting they have similar lipoprotein 363 
utilization or incorporation.     364 
 Some adaptive mutations enhance CD81-LEL and NMAb sensitivity. E2 is the major 365 
viral target of neutralizing antibodies during infection. Many of the most effective broadly NMAbs 366 
block interaction between E2 and CD81, one of the key HCV entry receptors (30, 31, 51, 52). 367 
Some growth-adaptive mutations in E2 were shown to increase inhibition by soluble CD81-LEL 368 
and NMAbs (37, 39, 40). To assess whether the identified mutations affected the binding of E2 369 
to CD81, we performed inhibition of infection assays with a soluble CD81-LEL (Fig 4A). A 370 
subset of adaptive mutant viruses (T416R, T563V, and L619T) were inhibited more efficiently by 371 
CD81-LEL than the parent JFH-1 virus (>5-fold decrease in EC50, P < 0.05), and thus an 372 
enhanced CD81-E2 interaction might contribute to the growth advantages of these viruses. 373 
However, most of the mutants were not more sensitive to CD81-LEL inhibition, which contrasts 374 
with some published growth-adaptive variants.  375 
 We next performed dose-response inhibition of infection assays with two broadly 376 
neutralizing anti-E2 NMAbs, H77.39 (Fig 4B) and HC84.26 (Fig 4C), both of which block 377 
interactions between E2 and CD81 (30, 31). H77.39 maps to an epitope centered on amino 378 
acids 415 and 417 and part of a larger epitope between positions 412-421. Residues within this 379 
region, especially W420, can influence CD81 interactions (24, 39). HC84.26 maps to conserved 380 
residues within the CD81 biding site between residues 441 and 446 and to residue 620 (H77 381 
residue numbers). Q412R, T416R, S449P, T563V, and L619T viruses were neutralized more 382 
efficiently by H77.39 than the parent JFH1 (>5-fold decrease in EC50, P < 0.0001) (Fig 4B) and 383 
T416R, S449P and T563V viruses were inhibited to a greater extent (>5-fold decrease in EC50, 384 
P < 0.05) by HC84.26 (Fig 4C). However, A579R, V626S, K632T and L644I viruses were 385 
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 HCV containing E2 adaptive mutations require CD81 and CLDN1 for infection. HCV 387 
entry is a complex process that requires several host factors including heparan sulfate 388 
proteoglycans (53, 54), low-density lipoprotein receptor (54–56), SR-BI (21, 57), CD81 (51, 58), 389 
CLDN1 (59), and occludin (OCLN) (60). Some E1 and E2 mutations cause altered entry factor 390 
usage or reduce dependence on a particular receptor (37, 39, 40, 61). To test whether our 391 
adaptive mutations changed CD81 or CLDN1 receptor dependency, we performed 392 
neutralization assays with antibodies against these host entry factors. However, all of the 393 
adaptive mutant viruses were inhibited by anti-CD81 and anti-CLDN1 similarly compared to the 394 
parental strain, suggesting little change in dependency on these receptors (Fig 5).  395 
 Growth-adaptive mutants are less-dependent on SR-BI for infection. Markedly 396 
different neutralization profiles were observed for the mutants when an anti-SR-BI antibody was 397 
used (Fig 6), as each variant was more resistant to antibody inhibition. Whereas the parental 398 
JFH-1 had a lower asymptote of 14% relative infection (i.e. resistant fraction), some mutant 399 
viruses appeared to be entirely resistant to anti-SR-BI treatment of Huh7.5 cells. Even the most 400 
sensitive mutant virus had a lower asymptote at 34% relative infection, 2.5-fold greater than 401 
parent. To confirm changes to SR-BI dependency, we generated SR-BIKO Huh7.5 cells using 402 
CRISPR/Cas9 gene editing (Fig 7). A clonal SR-BIKO Huh7.5 line, clone 16, was selected for 403 
further study. Clone 16 was confirmed to lack SR-BI expression (Fig 7A) and exhibited a 404 
moderately impaired capacity to support HCV cell entry (Fig 7B). Importantly, this phenotype 405 
was restored completely by trans-complementation from a lentiviral vector (Fig 7B). Paired 406 
infections of control (GFP) and SR-BI (SR-BI + GFP) trans-complemented SR-BIKO cells with 407 
WT and mutant HCV corroborated the anti-SR-BI antibody data: the mutants showed greater 408 
infection in cells lacking SR-BI compared to the parental virus (Fig 7C). Thus, growth adaptation 409 
in Huh7.5 cells resulted in the emergence of viruses with less dependency on SR-BI for 410 
infection. To assess whether the mutations had a similar effect on other HCV genotypes, we 411 
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clone encoding the structural genes of the genotype 1 H77 isolate (H77/JFH-1). We performed 413 
paired infections of control and SR-BI trans-complemented SR-BIKO cells with the H77/JFH-1 414 
mutants and again observed less dependence on SR-BI for infection with the mutant viruses 415 
(Fig 7D). Finally, we explored whether deletion of SR-BI from Huh7.5 cells differentially affected 416 
the attachment of parent and mutant viruses. Notably, the attachment of all viruses to the SR-BI 417 
gene-edited cells was similar, suggesting the mutations likely affect a post-attachment 418 
interaction step that requires SR-BI (Fig 7E).  419 
 Our results suggested that all of the growth adaptive mutations identified in our screen 420 
modulated the SR-BI dependence of HCV for entry into target cells. When we mapped the 421 
positions of the growth adaptive mutations on the E2 core structure (19), we found that four of 422 
the residues (L619T, V626S and K632T, and L644I)  were proximal to one another, with K632T, 423 
and L644I directly adjacent in an anti-parallel beta hairpin (Fig 7F). This clustering suggests a 424 
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DISCUSSION  426 
 The study of single amino acid viral variants has facilitated advances in our 427 
understanding of host-pathogen interactions. However, classical methods of producing viral 428 
variants rely on stochastic errors of the viral polymerase to generate mutations. Such 429 
approaches can be an inefficient means of producing new mutants even when selective 430 
pressure is applied.  This approach may fail to explore all possible amino acid substitutions, as 431 
multiple nucleotide changes at a single codon are less likely. The limitation of relying on 432 
randomly occurring mutations is particularly problematic for HCV, as it is relatively slow growing 433 
in culture. By molecularly engineering variability into E2 and producing our SDSM library we 434 
circumvented the need to wait months for mutations to arise in culture. Where previous attempts 435 
to identify new culture adaptive mutations yielded few mutations, we selected for many variants 436 
within three tissue culture passages.  437 
 Previous studies of growth-enhancing E2 mutations were limited to a few sites with E2, 438 
between positions 412-421 and at positions 451 and 563 (38–41). These mutations increased 439 
the sensitivity of the virus to inhibition by CD81-LEL and anti-HCV NMAbs targeting the E2-440 
CD81 interaction. These mutations may elicit a more open E2 conformation, which promotes 441 
interactions with CD81 or other entry factors at the cost of greater exposure of the NMAbs that 442 
block access to the CD81 binding site on E2. Additionally, some of these prior mutations altered 443 
the dependence of HCV on SR-BI and caused a shift in the buoyant density profile of the 444 
infectious viruses. In comparison, our panel of mutations were distributed more evenly across 445 
the E2 protein. Four substitutions (Q412R, T416R, S449P and T563V) were proximal to the 446 
previously described positions, however the remaining five mutations (A579R, L619T, V626S, 447 
K632T, and L644I) were at unique positions within E2.  448 
 The increased sensitivity to NMAb and CD81-LEL inhibition by growth-enhancing E2 449 
mutations may represent a trade-off made by the virus in the face of humoral immune pressure, 450 
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hypothesis, an alignment of all genotype 2 E2 amino acid sequences in the ViPR database 452 
(http://www.viprbrc.org/) revealed that our adaptive mutations were present at low frequencies 453 
or absent from most HCV isolates (Table 3). A subset of our mutations, Q412R, T416R, S449P, 454 
T563V, and L619T, were more sensitive to NMAb inhibition than the parental virus. Of these, 455 
T416R, T563V and L619T also were more sensitive to inhibition by CD81-LEL. T416R falls 456 
within the epitope of H77.39 and correspondingly is neutralized more efficiently by this antibody. 457 
The S449P mutation eliminates a predicted N-linked glycosylation site at N448 near the CD81 458 
binding site, which might enhance NMAb potency by reducing steric hindrance of the glycan. At 459 
present, the effects of other residues on the potency of neutralization by H77.39 and HC84.26 460 
are more challenging to model. Structural data for the binding of these antibodies to E2 are not 461 
available, and some of the residues are not visible in the crystal structures of the E2 core. 462 
Residues that are not proximal to the footprints of H77.39 and HC84.26 could affect 463 
neutralization potency indirectly, perhaps via altered lipoprotein association or changes in the 464 
global conformation of E2.  465 
 Q412R and S449P were more sensitive to H77.39 and HC84.26 antibody neutralization 466 
without showing increased inhibition by CD81-LEL. This suggests that increased exposure of 467 
the CD81 binding site is not responsible exclusively for enhanced anti-E2 neutralization. We 468 
also identified growth adaptive mutations in E2 (e.g., A579R and K632T) that did not render the 469 
virus more susceptible to neutralizing antibodies, although further studies are warranted. These 470 
mutants could be more sensitive to NMAbs targeting different epitopes. Alternatively, these 471 
mutations may adapt the virus to Huh7.5 cells but not to cell targets in vivo.  472 
 Mutations in E1 and E2 can alter the dependence of HCV on particular receptors or even 473 
cause a shift in receptor utilization (37, 39, 40, 61). We tested whether our growth adapted 474 
viruses had different entry factor utilization. Antibodies to CD81 and CLDN1 showed little 475 
difference in potency between the mutant and parental viruses; thus, the mutant viruses 476 
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cells were pretreated with anti-SR-BI antibodies. Parental virus was neutralized efficiently with a 478 
90% reduction at high antibody concentrations. However, all of the growth adapted viruses were 479 
resistant to the effects of anti-SR-BI, a finding which was corroborated using CRISPR/Cas9 480 
generated SR-BIKO and trans-complemented cells. Additionally, H77/JFH-1 clones bearing 481 
homologous mutations to JFH-1 S449P, L619T and L644I, similarly were resistant to SR-BI 482 
deletion, suggesting the mutations have a conserved role in modulating the SR-BI interaction. 483 
As changes to lipoprotein incorporation could contribute to the observed SR-BI phenotype of 484 
some growth adaptive mutants, we analyzed buoyant density profiles for relative infectivity. 485 
However, all of our growth adaptive mutants had virtually identical profiles relative to parental 486 
virus. This observation suggests that the altered SR-BI usage may not be a function of changes 487 
to lipoprotein incorporation. Consistent with this idea, HCV uses SR-BI at multiple points in the 488 
entry pathway, as an attachment factor via interactions with virus associated lipoprotein and 489 
also during post-attachment steps by directly interacting with E2 (62). As deletion of SR-BI did 490 
not differentially affect attachment of parent or variant HCV to Huh7.5 cells, these mutations 491 
may alter a post-attachment interaction with SR-BI.  492 
 While it is known that deletion of HVR1 abrogates binding of E2 to SR-BI, the details of 493 
this interaction remain unclear. Our findings, along with data from previous studies, suggest that 494 
reduced SR-BI dependence for infection is a common feature of growth-enhancing E2 495 
mutations (at least in cell culture) and that residues distributed across the E2 protein can 496 
modulate the interaction with SR-BI. As four of the sites of growth adaptive mutations we 497 
identified with altered SR-BI dependency were proximal to each other, we speculate this could 498 
represent part of a possible SR-BI binding site in E2. The molecular basis for why our mutants 499 
show less dependency on SR-BI awaits more detailed structural or biochemical resolution of the 500 
E2 and SR-BI interaction.  501 
 In summary, we developed a novel E2 JFH-1 mutant library with significant diversity and 502 
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summarized in Table 4, and varied with respect to NMAb and CD81-LEL inhibition sensitivity 504 
and SR-BI-dependence. More broadly, these results demonstrate the utility of libraries of variant 505 
viruses to address questions in HCV biology, especially as it relates to receptor interactions and 506 
possibly, immune escape. The SDSM method provides a depth of variability that can be 507 
employed rapidly for discovery of novel HCV variants with unique functional profiles. 508 
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FIGURE LEGENDS 716 
Figure 1. Generation of a SDSM library of infectious HCV and selection of growth 717 
adaptive mutations. A. Summary of the strategy used to generate the SDSM E2 library. Three-718 
hundred and twenty degenerate (NNN) primer sets were used to randomize each codon in the 719 
ectodomain of E2, excluding cysteine residues. These plasmid libraries were grouped into sets 720 
of 10 sequential codons. E1-E2 fragments amplified by PCR from these plasmid pools were 721 
used to generate 32 pools of mutant viruses. B. Amplicon sequencing results for the plasmid 722 
libraries. The frequency of mutant codons at each position within the library is shown. The ideal 723 
mutant frequency is 10% using our approach (red dashed line).    724 
Figure 2. Growth kinetics of viruses bearing the dominant mutations identified by 725 
serial passage of E2 mutant pools. A. Huh7.5 cells were infected with each of the nine 726 
mutants selected for study and parent virus at a MOI of 0.1 based on titers calculated using the 727 
TCID50 method. Input virus was removed 6 h after infection and samples collected every 24 h for 728 
7 days. Supernatant viral titers were analyzed by FFA. B. Cultures of Huh7.5 cells were infected 729 
as in (A) at a MOI of 0.05. Inoculum (black bars) and titers of virus from supernatant at day 5 730 
(grey bars) were determined using the TCID50 method. Error bars represent standard error of 731 
the mean (SEM) and dashed lines indicate the limit of detection of the assays. Asterisks indicate 732 
differences that are statistically significant (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 733 
0.0001; ns, not significant). The results are the average of three independent experiments 734 
performed in duplicate. 735 
Figure 3. Growth enhancing mutations do not change buoyant density profiles. 736 
Virus-containing media was layered over 5-50% sucrose gradients and ultracentrifuged at 737 
105,000 x g for 17 hours at 4oC. Twelve 1 mL fractions were collected. The density of the liquid 738 
in each fraction was determined using a refractometer, and viral titers and genome copies in 739 
each fraction were quantified by FFA and RT-PCR, respectively. In each panel, the percent of 740 
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total genome copies in the bottom, with a control plot for the parental virus shown in red. The 742 
mutants are displayed in the panels as follows: Q412R (A); T416R (B); S449P (C); T563V (D); 743 
A579R (E); L619T (F); V626S (G); K632T (H); and L644I (I). Panel (J) includes a comparison 744 
between parent JFH-1, the T416R mutant and J6/JFH-1 viruses run as a control to confirm 745 
differences in buoyant density profiles could be measured using our experimental approach. 746 
Each point represents the mean of three independent experiments with error bars representing 747 
SEM.     748 
Figure 4. A subset of growth enhanced mutants are more sensitive to CD81-LEL 749 
and NMAb inhibition. Parental or mutant viruses were pre-incubated with a dilution series of 750 
CD81-LEL (A) or anti-E2 antibodies H77.39 (B) or HC84.26 (C) for 1 h at 37oC and then added 751 
to Huh7.5 cells. Infection was quantified 72 h later by FFA. EC50 values were determined by 752 
non-linear regression analysis. The left panels are representative dose response curves for 753 
parental virus and the mutants. The fold decrease in EC50 value for the antibody treatment 754 
relative to parental virus is plotted in the right panel. Asterisks indicate differences that are 755 
statistically significant (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not 756 
significant). Error bars represent SEM. The results are the average of three independent 757 
experiments performed in triplicate or quadruplicate. 758 
Figure 5. The dependence on CD81 and CLDN1 for growth adapted mutants is 759 
similar to the parental virus. Huh7.5 cells were pre-incubated with a dilution series of anti-760 
CD81 (A) or anti-CLDN1 (B) for 1 h at 37oC and then infected with parental and growth adapted 761 
mutant viruses. Infection was quantified 72 h later by FFA and EC50 values determined by non-762 
linear regression. For each mutant virus, the fold change in EC50 value for the antibody 763 
treatment relative to parental virus is plotted. Asterisks indicate differences that are statistically 764 
significant (*, P < 0.05; **, P < 0.01; ns, not significant). Error bars represent SEM. The results 765 
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Figure 6. Growth enhanced mutants are less dependent on SR-BI for infection. 767 
Huh7.5 cells were pre-incubated with a dilution series of anti-SR-BI for 1 h at 37oC and then 768 
infected with parental and mutant viruses. Infection was quantified 72 h later by FFA. In each 769 
panel, the dose-response curve for a single mutant virus is displayed with the same control 770 
dose-response curve for parental virus. The mutants are displayed in the panels as follows: 771 
Q412R (A); T416R (B); S449P (C); T563V (D); A579R (E); L619T (F); V626S (G); K632T (H); 772 
and L644I (I). Error bars represent SEM. The results are the average of three independent 773 
experiments performed in quadruplicate 774 
Figure 7. Generation of SR-BI deficient Huh7.5 cells. A. Parental Huh7.5 cells or 775 
Huh7.5 SR-BIKO clone cell populations were stained with isotype control or SR-BI specific 776 
antibodies and analyzed by flow cytometry. B. The relative titers of a single stock of HCV were 777 
determined by limiting dilution assay on parental Huh7.5 cells or Huh7.5 SR-BIKO clonal cells 778 
either not expressing a transgene (‘mock’) or transduced with lentiviral particles to express GFP 779 
or SR-BI. Values represent the mean TCID50/mL value and the error bars indicate SEM of three 780 
independent assays. C. SR-BIKO Huh7.5 cells stably expressing GFP or GFP and SR-BI were 781 
infected with parental or variant virus. The relative infection of GFP-only cells compared to GFP 782 
and SR-BI co-expressing cells is shown. Error bars represent SEM. Asterisks indicate 783 
differences that are statistically significant (*, P < 0.05; ***, P < 0.001; ****, P < 0.0001). The 784 
results are the average of three independent experiments performed in quadruplicate. D. SR-785 
BIKO Huh7.5 cells stably expressing GFP or GFP and SR-BI were infected as described in (C) 786 
using parental H77/JFH-1 and H77/JFH-1 variant viruses bearing corresponding mutations to 787 
JFH-1 S449P, L619T, and L644: S449P, L615T and L640L, respectively. E. SR-BIKO Huh7.5 788 
cells stably expressing GFP or GFP and SRBI were incubated with parental or variant virus or 3 789 
h on ice. Cells were washed extensively, cellular RNA was harvested, and HCV genome copies 790 
were quantified by qRT-PCR. The relative attachment to GFP-only cells compared to GFP and 791 
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differences were observed. The results are the average of three independent experiments 793 
performed in duplicate.  F. Ribbon diagram of the E2 core structure (PDB ID: 4MWF) (19) 794 
illustrating the locations of the adaptive mutations identified in this study (red spheres) and 795 
residues essential for CD81 binding (blue spheres, amino acid positions 529-535). Q412 and 796 
T416 were excluded as they fall within a disordered region.  797 
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Table 1: Mutations selected by serial passage of HCV E2 mutant pools 799 
Positions of 
mutations in E2 
of P0 virus 
Positions of P3 putative 
adaptive mutations identified 
by consensus sequencing 
Amino acid substitutions identified 
by colony sequencing (% of 
colonies bearing the substitution) 









R (33%), A (11%), D (3%) 
 
I411, L413 
414-423 T416 R (16%), K (10%), N (5%), V (5%), A 
(5%), G (3%), D (3%) 
I414, N415, N417, 
G418 
445-455 S449 No Data*  
562-573 T563 V (33%), L (33%), I (2%) T565 
574-583 A579 R (17%), L (10%), M (7%)  
618-628 L619 T (34%), E (9%), I (2%) W620 
 V626 S (15%), T (2%), Q (2%), E (2%), R 
(2%) 
 
629-638 K632 T (62%) I630 
639-649 L644 I (32%), V (14%) A646 
* Consensus sequencing suggested only a proline substitution. 800 
Each pool of E2 mutants was passaged three times in tissue culture. Subsequently, viral RNA 801 
was harvested, cDNA generated, and E1-E2 amplified by PCR and Sanger sequenced across 802 
the sites of engineered mutations within E2. Eight of the thirty-two pools had changes to the E2 803 
consensus sequence: 404-413, 414-423, 445-455, 563-573, 574-583, 618-628, 629-638, and 804 
639-649. The E1-E2 fragments from these samples were cloned, and plasmids from individual 805 
colonies were sequenced to determine the specific amino acid substitutions selected from each 806 
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Table 2: Genome copy number to TCID50 ratios for growth enhanced mutants 809 
 810 
Huh7.5 cell cultures were infected at a MOI of 0.05 with each mutant and the parental virus. The 811 
inoculum was washed off and 5 days post infection nascently produced virus was collected and 812 
titered by the TCID50 method. Genome copies were measured by RT-PCR. Values are the 813 
mean of three experiments performed in duplicate.  814 
  815 
Virus Parent Q412R T416R S449P T563V A579R L619T V626S K632T L644I 
Genome Copy 
per TCID50 
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Table 3: Number of genotype 2 sequences in the ViPR database bearing each amino acid 816 
at the site of adaptive mutation.  817 
 818 
 819 
All HCV genotype 2 E2 amino acid sequences in the ViPR database were aligned and the 820 
number of sequences containing each residue at the sites of our adaptive mutations was 821 
determined.    822 
Q412R T416R S449P T563V A579R L619T V626S K632T L644I 
Ala (A) 4 33 1338 1 252 
Arg (R) 31 1 9 1 
Asn (N) 136 82 1 
Asp (D) 13 2 212 
Cys (C) 1 
Gln (Q) 3986 1 1 4 
Glu (E) 181 110 2 1 
Gly (G) 9 3 11 1 
His(H) 36 1 3 
Ile (I) 2 1 7 1 
Leu (L) 4 117 469 9 417 
Lys (K) 5 8 4 460 
Met (M) 12 1 6 
Phe (F) 1 2 41 
Pro (P) 45 2 3 
Ser (S) 231 803 1868 220 1 
Thr (T) 28 3211 5 528 12 1 
Trp (W) 14 
Tyr (Y) 
Val (V) 1 3 444 1 
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Q412R Q412 1.7 19 8.4 2.1 2.2 2.0 82% 58% 
T416R T416 2.3 63 6.5 5.5 2.8 1.4 72% 57% 
S449P S449 2.0 46 11 1.5 0.91 1.9 100% 59% 
T563V T561 3.3 26 9.7 6.2 1.4 1.3 55% 55% 
A579R (N577) 3.8 2.8 1.0 1.1 2.6 1.5 34% 33% 
L619T L615 2.6 28 6.0 10 3.3 1.7 100% 61% 
V626S I622 1.5 4.9 2.6 1.6 2.6 2.7 57% 44% 
K632T K628 1.2 1.2 1.7 0.44 2.1 4.4 36% 44% 
L644I L640 1.3 3.8 4.5 1.7 1.2 2.7 53% 58% 
*Fold reduction  824 
**Fold increase 825 
***Resistant fraction  826 
A summary of the properties of the mutants identified in this study. Fold decrease relative to 827 
parent is listed for RNA:TCID50. The fold change in EC50 (increase or decrease) is listed for all 828 
dose-response inhibition assays. For the SR-BI antibody dose response or infection of SR-BIKO 829 
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